Info Type


About The National Ovarian Cancer Coalition (08-29-2018)

Where do you go when you’re first delivered the news: “You have cancer”? For many women diagnosed with ovarian cancer, the answer is the National Ovarian Cancer Coalition (NOCC). With more than 80 chapters nationwide, a Web site (www.ovarian.org)... Continue Reading

Opdivo® (nivolumab) Approved for Treatment of Small Cell Lung Cancer (08-23-2018)

The U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for the treatment of metastatic small cell lung cancer (SCLC) whose cancer has progressed after platinum-based chemotherapy and at least one other line of therapy.1 About Small... Continue Reading

FDA Approves Lenvatinib for Treatment of Advanced Hepatocellular Cancer (08-20-2018)

The U.S. Food and Drug Administration (FDA) approved the kinase inhibitor LENVIMA® (lenvatinib) for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). This approval was based on results from REFLECT, where LENVIMA... Continue Reading

Melanoma Linked with CLL, Wilmot Recommends Close Monitoring (08-17-2018)

While studying a large group of individuals with chronic lymphocytic leukemia (CLL), a Wilmot Cancer Institute scientific team made an important discovery — these patients had a sizable 600 percent higher risk of melanoma, the most dangerous form of... Continue Reading

FDA Approves Iobenguane I 131 (Azedra) for Rare Neuroendocrine Tumors (08-2-2018)

The US Food and Drug Administration (FDA) today approved Azedra (iobenguane I 131) for the treatment of pheochromocytoma or paraganglioma, which are rare neuroendocrine tumors of the adrenal gland and other tissue areas. About Pheochromocytoma and Paraganglioma Pheochromocytomas... Continue Reading

What is The Optimal Duration of Adjuvant Hormone Therapy for Early Stage Breast Cancer? (07-25-2018)

Currently it is recommended that most postmenopausal women with hormone receptor–positive early stage breast cancer be treated with 5 additional years of aromatase inhibitor (AI) therapy following completion of an initial 5 years of treatment. The optimal... Continue Reading

Tibsovo Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and an IGH1 Mutation (07-23-2018)

Tibsovo® (ivosidenib) has been granted approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation... Continue Reading

FDA Approves Kisqali as Initial Endocrine Therapy for Advanced Breast Cancer (07-23-2018)

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor... Continue Reading

Nimotuzumab in Combination With Concurrent Radiotherapy and Cisplatin Is Active in Locally Advanced SCCHN (07-19-2018)

Nimotuzumab in combination with concurrent radiotherapy and cisplatin provides significant clinical benefits in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). About Head and Neck Cancer Head and neck cancers include... Continue Reading

FDA Approves Xtandi for Treatment of Castration-resistant Prostate Cancer (07-17-2018)

On July 13, 2018, the Food and Drug Administration approved Xtandi (enzalutamide) for patients with castration-resistant prostate cancer (CRPC).  This approval broadens the indicated patient population to include patients with both non-metastatic CRPC... Continue Reading

« Previous PageNext Page »